Expanding our possible business for next decade
Proceeding Alliance with our business partners for innovative business development.
Genome Editing - EmendoBio, Inc.
About EmendoBio Inc.
Emendo Biotherapeutics is a pioneering, next generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, Emendo’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our technology enables us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered untreatable.
Microbiome - MyBiotics Pharma Ltd.
MyBiotics is a pre-clinical platform microbiome company closing the gap between probiotics and clinical microbiome products and treatments.
MyBiotics is a microbiome company aiming to improve people’s lives and health by greatly improving existing probiotic solutions.
MyBiotics’ team of experts and scientists developed a novel robust method for formulation, delivery and colonization of beneficial live bacteria in patients, with long-term health benefits. Based on this proprietary innovation, MyBiotics developed 3 main technologies – MyCrobe, SuperDonor and Super Donor Select that target specific medical indications, and tested the technology in a real environment.